Nationwide experiences with trough levels, durability, and disease activity among inflammatory bowel disease patients following COVID-19 vaccination.
Tamás ResálPéter BacsurMiklós HorváthKata Judit SzántóMariann RutkaAnita BálintAnna FábiánRenáta BorZoltán SzepesJános FeketeKlaudia FarkasPál MihellerTamás MolnárPublished in: Therapeutic advances in gastroenterology (2023)
Anti-SARS-CoV-2 vaccination is considerably efficacious in IBD patients, with mRNA vaccines promoting better antibody levels. The negative impact of combined biological treatment, especially with high adalimumab drug levels, on serological response to vaccination should be considered. Although midterm durability of vaccination is encouraging, more data are needed to expand the existing understanding on this issue.
Keyphrases
- sars cov
- disease activity
- rheumatoid arthritis
- systemic lupus erythematosus
- juvenile idiopathic arthritis
- rheumatoid arthritis patients
- newly diagnosed
- coronavirus disease
- end stage renal disease
- ejection fraction
- ankylosing spondylitis
- mental health
- respiratory syndrome coronavirus
- electronic health record
- emergency department
- binding protein
- deep learning
- patient reported
- smoking cessation